AUTHORS
Lacey Williams, MD, Esteban Pena Ayala, MD2, Lukas Ronner, MD MSCR3, Xiuya Chang4, Rahul Kumar Thakur, MD5, Sarah Skuli, MD, PhD6, Akmaljon Salimov7, Andrew Matthews, MD8, Paige Pammer, MD9, Jonathan Galeotti10, Angela Nichols, NP11, Katie Moffitt12, Daniel T Peters, MD13, Jose Martinez, MD, PhD14, Anastasia Ivanova, PhD15, Irum Khan, MD16, Yasmin Abaza, MD17, Daniel R Richardson, MD,MSc,MA18, Pamela J. Sung, MD PhD19, Catherine Lai, MD, MPH20, Joshua F. Zeidner, MD21
AFFILIATIONS
1 University of North Carolina, CHAPEL HILL, North Carolina, United States
2 University of North Carolina, Chapel Hill, North Carolina, United States
3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of North Carolina, Chapel Hill, North Carolina, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 University of Cincinnati, Cincinnati, Ohio, United States
7 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Drexel University College of Medicine, Philadelphia, United States
10 University of North Carolina, Chapel Hill, North Carolina, United States
11 University of North Carolina, Chapel Hill, North Carolina, United States
12 University of North Carolina, Chapel Hill, North Carolina, United States
13 Atrium Health, Charlotte, North Carolina, United States
14 University of North Carolina, Chapel Hill, North Carolina, United States
15 University of North Carolina, Chapel Hill, North Carolina, United States
16 Northwestern University, Chicago, Illinois, United States
17 Northwestern University, Chicago, Illinois, United States
18 University of North Carolina, Chapel Hill, North Carolina, United States
19 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
20 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
21 University of North Carolina, Chapel Hill, North Carolina, United States
ABSTRACT
Intro
TP53-mutated (TP53m) acute myeloid leukemia (AML) is associated with dismal outcomes with a median overall survival (mOS) 5-6 months for both intensive and non-intensive chemotherapy regimens. For younger/fit patients (pts), intensive induction therapy is often considered while hypomethylating agents (HMAs) with or without venetoclax remain the standard for older/unfit pts. However, it is unclear whether intensive chemotherapy improves outcomes in younger/fit pts given the dismal outcomes seen with all treatment modalities. We set out to assess and compare clinical outcomes of newly diagnosed TP53m AML pts treated with intensive versus low-intensity therapy in a multi-institutional real-world analysis.
Methods
We conducted a multi-center real-world analysis of pts with newly diagnosed TP53m AML treated between 2015-2024 across four institutions (University of North Carolina, University of Pennsylvania, Roswell Park, and Northwestern University). Pts received next-generation sequencing (NGS) mutational panel at diagnosis including TP53 based on local testing. Biallelic TP53m AML was defined byTP53m variant allele fraction (VAF) 50%, 2 TP53 mutations, or TP53mwith loss of 17p by cytogenetics or FISH consistent with 2022 WHO criteria. All other TP53m cases were classified as monoallelic or unknown (if VAF was unknown). Frontline treatment regimens were stratified by intensive chemotherapy (IC) including 7+3 with or without cladribine, CPX-351, or clofarabine, cytarabine, G-CSF (CLAG) with or without investigational therapies. Low-intensity chemotherapy (LIC) was defined as HMAs with or without venetoclax. Other treatment regimens included targeted therapies and clinical trial approaches. Categorical variables were compared using the Chi-square test or Fisher’s exact test, as appropriate. Kaplan-Meier survival analysis was used to estimate overall survival, with group comparisons performed using the log-rank test. Survival across treatment groups was assessed with Holm adjustment for multiple comparisons. Analyses were conducted using SAS software. Percentages were calculated among pts with available data for each variable.
Results
Overall, 581 pts were included in this analysis; 289 (56.7%) were male, 406 (82.9%) were Caucasian, 52 (10.6%) were African American, 12 (2.5%) pts were Asian, and 20 (4.1%) were other/multiracial. Median age was 69yr (range 32-93), with 166 pts 75yr (28.6%). 207 (36%) were categorized as AML-MR. 114 (20%) had therapy-related AML. Among 458 pts with sufficient data to determine TP53 allelic status, 83 (18%) were monoallelic and 375 (82%) were biallelic; allelic status was indeterminate in 123 pts.
Overall, mOS was 4.7mo (95% CI: 4.0, 5.3) and similar in pts with biallelic vs monoallelic TP53m (mOS 4.2mo 95% CI: 3.2, 5.2 vs 5.3mo (95% CI: 4.80, 8.41)). Clinical outcomes were then compared in patients who received IC vs. LIC. 137 pts (26%) underwent treatment with IC; mOS was 8.6mo. For pts with biallelic vs monoallelic TP53m treated with IC, mOS were 7.5 (95% CI: 6.4, 9.7) and 6.9 (95% CI: 5.2, 23.0) respectively. 202 pts (35%) were treated with LIC including HMA+venetoclax (mOS 5.3mo) and HMA alone (median OS = 4.2mo). 22 pts (4%) were managed with supportive care only (mOS <1mo). There were significant differences in OS across treatment groups, including IC vs HMA (p=0.010), and IC vs HMA+venetoclax (p=0.012).
70 pts (23%) were treated with novel agents on clinical trial and demonstrated improved median OS compared to those treated with standard of care regimens (7.5 vs 3.2mo, log-rank p=0.05), including those that did not undergo allogeneic stem cell transplant (alloSCT). 81 (15%) pts underwent alloSCT and had significantly improved mOS compared with those who did not undergo alloSCT (mOS 15.9mo vs 3.2mo, p<0.001).
Conclusion
In this multi-institution cohort of pts with TP53-mutated AML, OS remained poor across treatment approaches. Improved survival outcomes with IC versus LIC and for investigational therapies may, in part, reflect selection of younger and/or more fit patients for these approaches, among other factors that are not adjusted for in the analyses. AlloSCT was associated with improved OS, although this analysis is subject to immortal time bias and few pts proceeded to transplant. These findings underscore the urgent need to develop novel therapeutic strategies, prioritize clinical trial options, and optimize alloSCT selection and timing for pts with TP53m AML.
DISCLOSURES
Lacey Williams, MD: Geron - Honoraria; Onviv - Honoraria; binaytara - Honoraria; Autolus - Honoraria